PharmassetX raised $0.05 million to develop PSX-514, a novel small-molecule drug and an FDA-designated orphan therapy for pouchitis, aimed at addressing a significant unmet need in the treatment of chronic inflammatory diseases.
PharmassetX raised $0.05 million to develop PSX-514, a novel small-molecule drug and an FDA-designated orphan therapy for pouchitis, aimed at addressing a significant unmet need in the treatment of chronic inflammatory diseases.